Posttreatment Lyme Disease Syndrome-What It Might Be and What It Is Not.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
20
1
2022
Statut:
ppublish
Résumé
Lyme disease is a multisystem disease caused by Borrelia burgdorferi infection and accounts for well-defined manifestations, appearing either at an early or late stage. Appropriate antibiotic therapy generally leads to a favorable outcome. Still, unspecific persisting symptoms such as fatigue, myalgia, arthralgia or cognitive dysfunction are reported by several patients months to years after adequate treatment. Their underlying pathophysiologic mechanism is unclear. However, there is no evidence for microbiological persistence in these cases and attempts to resolve the symptoms by repeated or prolonged antibiotic treatment have not been convincingly successful, but they may rather be harmful. To narrow down the controversially handled entity of posttreatment Lyme disease syndrome (PTLDS) and to avoid overdiagnosis and overtreatment, case definitions have been proposed, acknowledging PTLDS as a complex of nonspecific, subjective symptoms, which are neither caused by ongoing infection nor by any other identifiable disease. PTLDS is mainly a diagnosis of exclusion and requires careful evaluation of differential diagnosis followed by counseling about optimal management in light of missing specific therapeutic options.
Identifiants
pubmed: 34042908
doi: 10.1097/INF.0000000000002772
pii: 00006454-202105001-00007
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S31-S34Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum. 1977; 20:7–17
Burgdorfer W, Barbour AG, Hayes SF, et al. Lyme disease-a tick-borne spirochetosis? Science. 1982; 216:1317–1319
Heininger U, Zimmermann T, Schoerner C, et al. [Tick bite and Lyme borreliosis. An epidemiologic study in the Erlangen area]. Monatsschr Kinderheilkd. 1993; 141:874–877
Strnad M, Hönig V, Růžek D, et al. Europe-wide meta-analysis of Borrelia burgdorferi Sensu Lato prevalence in questing Ixodes ricinus ticks. Appl Environ Microbiol. 2017; 83e00609e00617
Huppertz HI, Bartmann P, Heininger U, et al.; Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health. Rational diagnostic strategies for Lyme borreliosis in children and adolescents: recommendations by the Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health. Eur J Pediatr. 2012; 171:1619–1624
Hofhuis A, van de Kassteele J, Sprong H, et al. Predicting the risk of Lyme borreliosis after a tick bite, using a structural equation model. PLoS One. 2017; 12:e0181807
Robert Koch-Institut. Seroprävalenz der Lyme-Borreliose bei Kindern und Jugend-lichen in Deutschland. Epidemiol Bull. 2012; 14:113–120
Schwartz AM, Hinckley AF, Mead PS, et al. Surveillance for Lyme disease—United States, 2008-2015. MMWR Surveill Summ. 2017; 66:1–12
Schotthoefer AM, Frost HM. Ecology and epidemiology of Lyme borreliosis. Clin Lab Med. 2015; 35:723–743
British Infection Association. The epidemiology, prevention, investigation and treatment of Lyme borreliosis in United Kingdom patients: a position statement by the British Infection Association. J Infect. 2011; 62:329–338
Stanek G, Fingerle V, Hunfeld KP, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011; 17:69–79
Sanchez E, Vannier E, Wormser GP, et al. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and Babesiosis: a review. JAMA. 2016; 315:1767–1777
Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006; 43:1089–1134
Guet-Revillet H, Levy C, Vallet C, et al. Lyme neuroborreliosis in children: report of nine cases and a review of the literature. Arch Pediatr. 2019; 26:133–137
Esposito S, Bosis S, Sabatini C, et al. Borrelia burgdorferi infection and Lyme disease in children. Int J Infect Dis. 2013; 17:e153–e158
Huppertz HI, Böhme M, Standaert SM, et al. Incidence of Lyme borreliosis in the Würzburg region of Germany. Eur J Clin Microbiol Infect Dis. 1999; 18:697–703
Gerber MA, Shapiro ED, Burke GS, et al. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N Engl J Med. 1996; 335:1270–1274
Association of State and Territorial Public Health Laboratory Directors. In: Proceedings of the Second National Conference on Serologic Diagnosis of Lyme Disease, Dearborn, MI, October 27–29, 1994. Washington, DC: Association of State and Territorial Public Health Laboratory Directors; 1994.
Steere AC, Strle F, Wormser GP, et al. Lyme Borreliosis. Nat Rev Dis Primers. 2016; 2:16090
Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep. 2019; 68:703
Lipsett SC, Branda JA, Nigrovic LE. Evaluation of the modified two-tiered testing (MTTT) method for the diagnosis of Lyme disease in children. J Clin Microbiol. 2019; 57:e00547–19
Shapiro ED, Wormser GP. Lyme disease in 2018: what is new (and what is not). JAMA. 2018; 320:635–636
Dessau RB, van Dam AP, Fingerle V, et al. To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis : a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis. . Clin Microbiol Infect. 2018; 24:118–124
Halperin JJ. Nervous system Lyme disease: is there a controversy? Semin Neurol. 2011; 31:317–324
Oksi J, Nikoskelainen J, Hiekkanen H, et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis. 2007; 26:571–581
Sood SK. Lyme disease in children. Infect Dis Clin North Am. 2015; 29:281–294
Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001; 345:85–92
Berende A, ter Hofstede HJ, Vos FJ, et al. Randomized Trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016; 374:1209–1220
Nemeth J, Bernasconi E, Heininger U, et al. Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016; 146:w14353
Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003; 60:1923–1930
Evison J, Aebi C, Francioli P, et al. [Lyme disease Part 3: prevention, pregnancy, immunodeficient state, post-Lyme disease syndrome]. Rev Med Suisse. 2006; 2:935–936, 938–940
Cerar D, Cerar T, Ruzić-Sabljić E, et al. Subjective symptoms after treatment of early Lyme disease. Am J Med. 2010; 123:79–86
Stupica D, Lusa L, Ruzić-Sabljić E, et al. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012; 55:343–350
Skogman BH, Croner S, Nordwall M, et al. Lyme neuroborreliosis in children: a prospective study of clinical features, prognosis, and outcome. Pediatr Infect Dis J. 2008; 27:1089–1094
Vázquez M, Sparrow SS, Shapiro ED. Long-term neuropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease. Pediatrics. 2003; 112:e93–e97
Hassett AL, Radvanski DC, Buyske S, et al. Role of psychiatric comorbidity in chronic Lyme disease. Arthritis Rheum. 2008; 59:1742–1749
Hassett AL, Radvanski DC, Buyske S, et al. Psychiatric comorbidity and other psychological factors in patients with “chronic Lyme disease”. Am J Med. 2009; 122:843–850
Sigal LH, Hassett AL. Contributions of societal and geographical environments to “chronic Lyme disease”: the psychopathogenesis and aporology of a new “medically unexplained symptoms” syndrome. Environ Health Perspect. 2002; 110suppl 4607–611